纤溶酶治疗糖尿病合并急性脑梗塞的临床观察

Observation of the treatment effect of fibrinogenase on diabetic patients with acute cerebral infarction

目的探讨纤溶酶治疗糖尿病性合并急性脑梗塞的疗效及其安全性。方法 98例糖尿病性脑梗塞患者,随机分成两组:治疗组和对照组,治疗组应用注射用纤溶酶100U加入250ml的0.9%氯化钠注射液中静滴;对照组则给予疏血通注射液6ml加入250ml的0.9%氯化钠注射液中静滴,用法均1次/日,连用2周,其余治疗相同。评价治疗前和治疗后2周的神经功能缺损以及临床疗效,观察不良反应,检测治疗前后血液纤维蛋白原(Fb)含量并进行比较。结果治疗后治疗组疗效显著优于对照组(P<0.05),纤维蛋白原(Fb)水平具有显著差异(P<0.05)。结论注射用纤溶酶对急性糖尿病性脑梗塞的近期疗效显著,能明显降低患者血液纤维蛋白原(Fb)含量,且无明显副作用。

Objective To investigate the effects and safety of fibrinogenase on acute cerebral infarction in diabetic patients.Methods 98 cases of diabetic cerebral infarction were randomly divided into two groups： treatment group and control group,treatment group received fibrinogenase 100u Intravenous drip once a day,other drug treatments were the same with control group;control group was administrated with Shuxuetong etc.The course of treatment continued for 14 days.Neurological function score and clinical efficacy were evaluated before treatment and after 2 weeks,and the adverse reactions were observed.Levels of blood Fibrinogen（Fb） were tested and compared before and after treatment.Results Comparing the patients of fibrinogenase group with those of the control group,neurological function score were significantly improved（P 0.05）.Fibrinogen（Fb） levels before and after treatment had significant difference（P0.05）.Conclusions Treatment of fibrinogenase for Injection has significant efficacy on acute cerebral infarction patients with diabetes.Fibrinogenase can significantly reduce the patient＇s blood fibrinogen（Fb） levels,and has no significant side effects.